Author Archives: Warren Woessner

In re Montgomery – “Unbounded” Inherency

In re Montgomery, App no. 2011-1376 (Fed. Cir. May 8, 2012) (a copy is available at the end of this post), a divided panel affirmed the Board’s decision that a claim to a “new use for an old compound” was … Continue reading

Posted in Anticipation | Tagged , , , , , , , , , , | Leave a comment

Otsuka v. Sandoz – Motivation Trumps Structure

The recent decision of the Fed. Cir. in Otsuka v. Sandoz, App. No. 2011-1126, -1127 (Fed. Cir. May 7, 2012) continues the courts admirable work in defining obviousness post-KSR. This case revisits the standards involved in making out a prima-facie … Continue reading

Posted in Obviousness | Tagged , , , | Leave a comment

Prometheus Q/A Results: Does Patent Eligibility Impact Biotech Research?

A guest post from shareholder Robin Chadwick of SLW. A quick survey of folks who read this blog indicates that funding for 5 Buy Cheap Cialis Soft 0% of respondents’ R&D is affected by whether or not a project was … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , | Leave a comment

Fed. Cir. Orders Briefing in Myriad Remand

On April 30th, in response to the Supreme Court’s GVR of the Myriad appeal (AMP et al. are still trying to get the claims to isolated DNA molecules and the use of a transgenic cell comprising the BRCA1 gene to … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , | 1 Comment